Print

RXi Pharmaceuticals (RXII) to Present at the 25th Annual ROTH Conference  
3/12/2013 6:23:54 AM

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company’s President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 25th Annual ROTH Conference on Tuesday, March 19th at 1:30pm PT. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi’s sd-rxRNA® technology platform.
//-->